Screener
Monopar Therapeutics MNPR Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Monopar Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026. Open the filing →
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
FAQ
- What is Monopar Therapeutics's debt-to-equity?
- Monopar Therapeutics (MNPR) reported debt-to-equity of 0× in Q1 2026.
- How has Monopar Therapeutics's debt-to-equity changed year-over-year?
- Monopar Therapeutics's debt-to-equity increased by 750.0% year-over-year, from 0× to 0×.
- What is the long-term trend for Monopar Therapeutics's debt-to-equity?
- Over 2 years (2022 to 2025), Monopar Therapeutics's debt-to-equity has grown at a -43.3% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Monopar Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude